Literature DB >> 22984273

The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile.

Marie Vanthuyne1, Vanessa Smith, Ellen De Langhe, Jens Van Praet, Seher Arat, Geneviève Depresseux, Rene Westhovens, Daniel Blockmans, Valérie Badot, Elie Cogan, Filip De Keyser, Frédéric A Houssiau.   

Abstract

OBJECTIVE: To report baseline and followup data on the first 438 patients with systemic sclerosis (SSc) included in the Belgian Systemic Sclerosis Cohort.
METHODS: According to LeRoy and Medsger's classification, 73 patients with limited SSc (lSSc), 279 with limited cutaneous SSc (lcSSc), and 86 with diffuse cutaneous SSc (dcSSc) were included. History was collected and clinical examination, blood tests, and paraclinical investigations were repeated. The Disease Activity Score (DAS) and Disease Severity Score (DSS) of several organ systems were computed. An organ system was considered to demonstrate SSc if the corresponding DSS was ≥ 1.
RESULTS: At baseline, patients with dcSSc had more general, joint/tendon, muscle, gastrointestinal, and kidney involvement. Mean DLCO was below normal in patients with lSSc, indicating unsuspected lung involvement. Patients with anti-Scl-70 had more vascular, skin, joint/tendon, and lung involvement. Patients with anti-RNA polymerase III had more skin and joint/tendon involvement compared to patients with anticentromere. Time to death was statistically shorter for patients with dcSSc. New-onset lung disease was the most common complication over time. No changes in DAS were observed. By contrast, the general and the skin DSS worsened in patients with lcSSc and lSSc, respectively. Fifteen percent of patients with lSSc shifted to lcSSc at Month 30, but neither serology nor capillaroscopy findings at baseline were helpful in identifying those at risk.
CONCLUSION: Our data indicate that the DSS can be used to define organ involvement in SSc. Differences can be seen between subsets classified not only according to cutaneous subtypes but also to autoantibody profile.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22984273     DOI: 10.3899/jrheum.120283

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries.

Authors:  Michele Iudici; Serena Fasano; Daniela Iacono; Barbara Russo; Giovanna Cuomo; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2013-11-19       Impact factor: 2.980

Review 2.  Update on juvenile systemic sclerosis.

Authors:  Ivan Foeldvari
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

Review 3.  Scleroderma: the role of serum autoantibodies in defining specific clinical phenotypes and organ system involvement.

Authors:  Robyn T Domsic
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

4.  High prevalence of occupational exposure to solvents or silica in male systemic sclerosis patients: a Belgian cohort analysis.

Authors:  Evelien De Decker; Marie Vanthuyne; Daniel Blockmans; Frederic Houssiau; Jan Lenaerts; Rene Westhovens; Benoit Nemery; Ellen De Langhe
Journal:  Clin Rheumatol       Date:  2018-02-23       Impact factor: 2.980

5.  Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis.

Authors:  Nina M van Leeuwen; Maaike Boonstra; Jaap A Bakker; Annette Grummels; Suzana Jordan; Sophie Liem; Oliver Distler; Anna-Maria Hoffmann-Vold; Karin Melsens; Vanessa Smith; Marie-Elise Truchetet; Hans U Scherer; René Toes; Tom W J Huizinga; Jeska K de Vries-Bouwstra
Journal:  Arthritis Rheumatol       Date:  2021-11-02       Impact factor: 15.483

6.  A prediction model for progressive disease in systemic sclerosis.

Authors:  Jessica Meijs; Anne A Schouffoer; Nina Ajmone Marsan; Theo Stijnen; Hein Putter; Maarten K Ninaber; Tom W J Huizinga; Jeska K de Vries-Bouwstra
Journal:  RMD Open       Date:  2015-12-01

7.  Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis.

Authors:  Jessica Meijs; Anne A Schouffoer; Nina Ajmone Marsan; Lucia J M Kroft; Theo Stijnen; Maarten K Ninaber; Tom W J Huizinga; Theodora P M Vliet Vlieland; Jeska K de Vries-Bouwstra
Journal:  RMD Open       Date:  2016-03-15

8.  Association of Anti-Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti-Topoisomerase I-Positive Systemic Sclerosis.

Authors:  Maaike Boonstra; Jaap A Bakker; Annette Grummels; Maarten K Ninaber; Nina Ajmone Marsan; Corrie M Wortel; Tom W J Huizinga; Suzana Jordan; Anna-Maria Hoffman-Vold; Oliver Distler; René E M Toes; Hans Ulrich Scherer; Jeska K de Vries-Bouwstra
Journal:  Arthritis Rheumatol       Date:  2020-09-29       Impact factor: 10.995

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.